Skip to content

Study · Randomized controlled trial · n = 36 · 2009

4 results

A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.

Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C

Journal of clinical pharmacology1 Feb 2009Cited by 23 (Europe PMC)

PMID19179298 (opens in a new tab)DOI10.1177/0091270008329552 (opens in a new tab)PepBankPUB-19179298
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In postmenopausal women, synthetic and recombinant calcitonin both reached peak plasma concentrations 15 minutes after dosing.

    In plain wordsIn postmenopausal women, synthetic and recombinant calcitonin both reached peak blood concentrations 15 minutes after dosing.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableTime to peak plasma concentration
    Study

    n = 36

    Comparator
    Recombinant salmon calcitonin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Time to peak concentration
    15 minutes
    both formulations

    Source sentences

    Summary
    For both formulations, peak plasma concentrations were obtained 15 minutes after dosage, and no statistically significant differences in the uptake of CT were observed.
    1 context sentence
    Summary · context
    The study was a single-blind, randomized study. Participants were 36 postmenopausal women 62 to 74 years old, randomly assigned to a comparison of dosing with ssCT (n = 12) or rsCT (n = 24) given in the morning at 08:00.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In postmenopausal women, synthetic and recombinant calcitonin showed no significant difference in uptake.

    In plain wordsIn postmenopausal women, synthetic and recombinant calcitonin showed no significant difference in uptake.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeCalcitonin uptake
    Study

    n = 36

    Comparator
    Recombinant salmon calcitonin
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    For both formulations, peak plasma concentrations were obtained 15 minutes after dosage, and no statistically significant differences in the uptake of CT were observed.
    1 context sentence
    Summary · context
    The study was a single-blind, randomized study. Participants were 36 postmenopausal women 62 to 74 years old, randomly assigned to a comparison of dosing with ssCT (n = 12) or rsCT (n = 24) given in the morning at 08:00.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, synthetic and recombinant calcitonin produced comparable CTX-I responses, with relative-change AUC of -250% x hours over four hours.

    In plain wordsIn postmenopausal women, synthetic and recombinant calcitonin produced comparable CTX-I responses over four hours.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableSerum CTX-I response
    Study

    n = 36

    Comparator
    Recombinant salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Serum CTX-I relative-change AUC
    −250 % x hours
    4-hour observation

    Source sentences

    Summary
    Measurement of bone resorption and cartilage degradation markers displayed comparable responses, with AUCs of relative change of serum CTX-I of -250% x hours and relative change of urine CTX-II of -180% x hours during the 4-hour observation period.
    1 context sentence
    Summary · context
    The study was a single-blind, randomized study. Participants were 36 postmenopausal women 62 to 74 years old, randomly assigned to a comparison of dosing with ssCT (n = 12) or rsCT (n = 24) given in the morning at 08:00.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, synthetic and recombinant calcitonin produced comparable CTX-II responses, with relative-change AUC of -180% x hours over four hours.

    In plain wordsIn postmenopausal women, synthetic and recombinant calcitonin produced comparable CTX-II responses over four hours.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableUrine CTX-II response
    Study

    n = 36

    Comparator
    Recombinant salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Urine CTX-II relative-change AUC
    −180 % x hours
    4-hour observation

    Source sentences

    Summary
    Measurement of bone resorption and cartilage degradation markers displayed comparable responses, with AUCs of relative change of serum CTX-I of -250% x hours and relative change of urine CTX-II of -180% x hours during the 4-hour observation period.
    1 context sentence
    Summary · context
    The study was a single-blind, randomized study. Participants were 36 postmenopausal women 62 to 74 years old, randomly assigned to a comparison of dosing with ssCT (n = 12) or rsCT (n = 24) given in the morning at 08:00.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.